Trillium Asset Management LLC reduced its stake in Stryker Co. (NYSE:SYK) by 1.4% during the 1st quarter, Holdings Channel reports. The firm owned 18,543 shares of the medical technology company’s stock after selling 267 shares during the period. Trillium Asset Management LLC’s holdings in Stryker were worth $3,663,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Gofen & Glossberg LLC IL lifted its position in Stryker by 6.8% in the fourth quarter. Gofen & Glossberg LLC IL now owns 6,899 shares of the medical technology company’s stock valued at $1,081,000 after acquiring an additional 441 shares during the last quarter. Fox Run Management L.L.C. purchased a new stake in Stryker in the fourth quarter valued at $270,000. First Citizens Bank & Trust Co. lifted its position in Stryker by 1.5% in the fourth quarter. First Citizens Bank & Trust Co. now owns 6,943 shares of the medical technology company’s stock valued at $1,088,000 after acquiring an additional 103 shares during the last quarter. BKD Wealth Advisors LLC lifted its position in Stryker by 2.0% in the fourth quarter. BKD Wealth Advisors LLC now owns 3,646 shares of the medical technology company’s stock valued at $572,000 after acquiring an additional 72 shares during the last quarter. Finally, Daiwa SB Investments Ltd. lifted its position in Stryker by 12.5% in the fourth quarter. Daiwa SB Investments Ltd. now owns 1,530 shares of the medical technology company’s stock valued at $240,000 after acquiring an additional 170 shares during the last quarter. Institutional investors and hedge funds own 74.71% of the company’s stock.
Shares of Stryker stock traded down $0.51 on Friday, reaching $185.12. 254,305 shares of the stock were exchanged, compared to its average volume of 1,302,334. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $199.85. The company has a quick ratio of 1.30, a current ratio of 2.12 and a debt-to-equity ratio of 0.68. The firm has a market cap of $69.27 billion, a price-to-earnings ratio of 25.32, a price-to-earnings-growth ratio of 2.26 and a beta of 0.84.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, April 23rd. The medical technology company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The business had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the previous year, the business posted $1.68 earnings per share. The business’s revenue was up 8.5% compared to the same quarter last year. Equities research analysts anticipate that Stryker Co. will post 8.15 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, June 27th. This represents a $2.08 annualized dividend and a yield of 1.12%. Stryker’s payout ratio is currently 28.45%.
In other Stryker news, VP Katherine Ann Owen sold 29,247 shares of the company’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $185.62, for a total transaction of $5,428,828.14. Following the transaction, the vice president now directly owns 11,131 shares in the company, valued at $2,066,136.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the company’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $188.21, for a total transaction of $508,167.00. Following the transaction, the chief financial officer now owns 23,333 shares in the company, valued at $4,391,503.93. The disclosure for this sale can be found here. Insiders have sold 111,550 shares of company stock worth $21,374,171 over the last 90 days. 7.20% of the stock is currently owned by company insiders.
A number of equities research analysts recently weighed in on the stock. Wells Fargo & Co boosted their price target on shares of Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Zacks Investment Research cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, April 12th. BTIG Research boosted their price target on shares of Stryker to $211.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Barclays upped their target price on shares of Stryker from $203.00 to $211.00 and gave the company an “overweight” rating in a report on Monday, April 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Stryker from $200.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. Seven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $196.89.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Recommended Story: Marijuana Stocks Investing Considerations
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.